<DOC>
	<DOCNO>NCT01928290</DOCNO>
	<brief_summary>This phase II trial study well combination chemotherapy work treat patient advanced stomach , gastroesophageal , esophageal cancer . Drugs use chemotherapy , irinotecan hydrochloride , oxaliplatin , leucovorin calcium , fluorouracil , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Advanced Stomach , Gastroesophageal , Esophageal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Formyltetrahydrofolates</mesh_term>
	<mesh_term>Tetrahydrofolates</mesh_term>
	<criteria>1 . Biopsyproven inoperable locally advanced , recurrent , metastatic cancer esophagus , stomach , gastroesophageal junction . 2 . Measurable disease define lesion accurately measure least one dimension ( long diameter record ) ≥10 mm CT scan , ≥20 mm chest xray , ≥10 mm caliper clinical exam . 3 . Prior single modality radiation therapy allow . 4 . At least 18 year age . 5 . ECOG performance status ≤ 2 6 . Normal bone marrow organ function define : 1 . Absolute neutrophil count ≥ 1,500/mcl 2 . Platelets ≥ 100,000/mcl 3 . AST ( SGOT ) /ALT ( SGPT ) ≤ 2.5 x IULN 4 . Creatinine ≤ IULN OR creatinine clearance ≥ 60 mL/min/1.73 m2 patient creatinine level institutional normal 5 . LVEF ≥ 50 % 7 . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control , abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , must inform treat physician immediately . 8 . Ability understand willingness sign IRB approve write informed consent document ( legally authorize representative allow ) . 9 . Patients already receive treatment FOLFIRINOX +/ trastuzumab may participate study data collect retrospectively meet inclusion criterion start therapy sign consent study participation move forward . 1 . Chemotherapy 6 month prior registration . 2 . History malignancy ≤ 5 year previous exception basal cell squamous cell carcinoma skin treat local resection carcinoma situ cervix . 3 . Receiving investigational agent time registration . 4 . Known untreated brain metastasis . These patient must exclude clinical trial poor prognosis often develop progressive neurologic dysfunction would confound evaluation neurologic adverse event . 5 . A history allergic reaction attribute compound similar chemical biologic composition agent use study . 6 . Previous therapy metastatic gastroesophageal cancer . Previous perioperative chemotherapy allow long duration without treatment great 6 months.. 7 . A history congestive heart failure , transmural myocardial infarction , symptomatic valvular disease , highrisk arrhythmia . 8 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 9 . Pregnant and/or breastfeeding . Patient must negative urine pregnancy test within 14 day study entry . 10 . Known HIVpositivity combination antiretroviral therapy potential pharmacokinetic interaction trastuzumab . In addition , patient increase risk lethal infection treat marrowsuppressive therapy . Appropriate study undertake patient receive combination antiretroviral therapy indicate . Inclusion Women Minorities Both men woman member race ethnic group eligible trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>